Characterization of Seasonal Influenza Vaccination Cross-Type Activity on Avian H5Nx
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 507191
Grant search
Key facts
Disease
Influenza caused by Influenza A virus subtype H5start year
2024Known Financial Commitments (USD)
$109,608.3Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Côté Marceline, Boivin Guy, Finzi AndrésResearch Location
CanadaLead Research Institution
University of OttawaResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Avian H5Nx viruses are subtypes of the influenza A virus, known as the highly pathogenic avian influenza (HPAI) group, that primarily infects birds but can occasionally infect humans and other animals. The most well-known of these is H5N1, which has caused numerous outbreaks and has a high mortality rate in birds with the potential to infect humans and other mammals, often resulting in severe illness and high fatality rates. Other H5Nx variants, such as H5N2, H5N5, H5N6, and H5N8, have also emerged, causing similar concerns. Whether the current seasonal influenza vaccine, which is formulated with one influenza A(H1N1) virus, one influenza A(H3N2) virus, can provide some level of protection against the circulating avian H5N1, H5N2, or other H5Nx, is unclear. Here, we propose to establish a platform for the rapid genotype to phenotypic characterization of avian H5 and Nx from surveillance activity in domestic and wild animals, and for the evaluation of seasonal vaccination and candidate vaccines. Our team has expertise in HPAI, viral immunology, molecular virology, One Health, veterinary science and viral surveillance, genomic epidemiology, data science and machine learning. Together, our efforts will set a new standard for rapid, effective, and collaborative responses to emerging infectious diseases.